Evidence map›Paper›PMID 34014447›Full record

ArticleJapanese journal of ophthalmology2021

Ocular findings in Japanese patients with hydroxychloroquine retinopathy developing within 3 years of treatment.

Hiroko Ozawa, Shinji Ueno, Akiko Ohno-Tanaka, Takao Sakai, Masayuki Hashiguchi, Mikiko Shimizu, Kaoru Fujinami, Seong Joon Ahn, Mineo Kondo, David J Browning and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Japanese journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Factors associated with early hydroxychloroquine-induced retinal toxicity in patients with systemic lupus erythematosus.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 4 countries.

Hiroko OzawaDepartment of Ophthalmology, Kawasaki Municipal Hospital, Kanagawa, Japan.
Shinji UenoDepartment of Ophthalmology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8550, Japan. ueno@med.nagoya-u.ac.jp.
Akiko Ohno-TanakaDepartment of Ophthalmology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
Takao SakaiDepartment of Ophthalmology, Chubu Rosai Hospital, Nagoya, Japan.
Masayuki HashiguchiDivision for Evaluation and Analysis of Drug Information, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Mikiko ShimizuDepartment of Pharmaceutics and Pharmacometrics, School of Pharmacy, Shujtsu University, Okayama, Japan.
Kaoru FujinamiDepartment of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
Seong Joon AhnDepartment of Ophthalmology, Hanyang University Hospital, Seoul, Korea.
Mineo KondoDepartment of Ophthalmology, Mie University Graduate School of Medicine, Tsu, Japan.
David J BrowningCharlotte, Eye, Ear, Nose, and Throat Associates, Charlotte, NC, USA.
Kei ShinodaDepartment of Ophthalmology, Saitama Medical University, Saitama, Japan.
Naoto YokogawaDepartment of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
Keio University · JPTokyo Metropolitan Tama Medical Center · JPCharlotte Eye Ear Nose & Throat Associates · USChubu Rosai Hospital · JPHanyang University Seoul Hospital · KRMie University · JPNagoya University · JPNational Hospital Organization · JPSaitama Medical University · JPShujitsu University · JP

Funding

Tokyo Metropolitan goverment the hydroxychloroquine retinopathy support program
6 · The paper itself

Abstract

purposeTo describe the characteristics of Japanese patients with hydroxychloroquine (HCQ) retinopathy developing within 3 years of treatment outset. STUDY

designRetrospective case series

methodsThree patients with HCQ retinopathy developing within 3 years of treatment outset have been identified in Japan since HCQ became available in 2015. Their medical charts, containing optical coherence tomography (OCT), fundus autofluorescence imaging, and visual field tests, were reviewed.

resultsThe treatment durations and cumulative doses until onset were 29-36 months and 182-326 g, respectively. The first patient had possible pre-existing maculopathy, although the abnormalities were ambiguous. The second and third patients had impaired renal function. The patients did not complain of severe visual disturbance at diagnosis, but visual field loss and disruption of the outer retinal segments consisting of a parafoveal pattern in the first case and a pericentral pattern (localized, 8 or more degrees from the center of the fovea) in the second and third cases were clearly observed on OCT. Even after HCQ discontinuation, their retinopathy showed slight progression on the visual field tests and OCT images. A blood sample was obtained from 1 patient on the day after HCQ discontinuation, and the whole blood level of HCQ was measured using validated liquid chromatography-tandem mass spectrometry. The HCQ level 27 h after the last dose was high, at 2240 ng/mL (suggested threshold > 1733 ng/mL).

conclusionOphthalmologic screening from the initiation of HCQ treatment detected 3 cases of HCQ retinopathy developing within 3 years of treatment outset, including a patient with a high blood level of HCQ.

Indexed as

Antirheumatic AgentsRetinal DiseasesHumansHydroxychloroquineJapanRetrospective StudiesTomography, Optical CoherenceAntirheumatic AgentsHydroxychloroquineFundus autofluorescenceHydroxychloroquine retinopathyMacular degenerationOCTVisual field

Identifiers

PMID34014447
OpenAlexW3160483486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.